Scott Rocklage currently serves as a Managing Partner at 5AM Ventures since 2004. 5AM Ventures is operational in Waltham, San Francisco, Massachusetts, and California. Dr. Scott Rocklage has over thirty years of experience in healthcare management experience. His strategic leadership has led to the Federal Drug Administration approval of U.S. New Drug Applications namely, Teslascan, Cubicin, and Omniscan.
Scott Rocklage Career Background
Before joining 5AM Ventures, Scott served as the Chief Operating Officer, President, and Chairman of Cubist Pharmaceuticals, Nycomed Salutar, and Amersham Health. During this time, he held several Research and Design positions. Rocklage also served as the Co-President and Executive Chairman of Ilypsa, Inc. Other positions held include Chairman of Novra Therapeutics, Inc and Chairman of the Cidara Board.
Rocklage obtained a Bachelor of Science degree in Chemistry from the University of California. He also holds a Ph.D. (Doctor of Philosophy) degree in Chemistry from the MIT (Massachusetts Institute of Technology). In 2005, Rocklage undertook a research study at MIT in the laboratory of a Nobel Prize Chemistry Winner known as Richard R. Schrock. Apart from that, Dr. Rocklage is responsible for the invention of over 30 U.S. Patents. He has also authored over 100 publications which are peer reviewed. Scott Rocklage’s education background has enabled him to have a vast range of skills and knowledge in the science and healthcare industry.
5AM Ventures is a leading firm in venture capital that focuses on life science companies that look forward towards the next generation. The company has over $1 billion in assets and supports entities that look for ways to develop solutions to healthcare needs using the combination of medicine and science. As a result, the companies that receive support from 5AM develop untraditional approaches that prevent, diagnose or treat various medical conditions and learn more about Scott.
The 5AM team comprises of people with strong scientific, medical, finance and business operational, finance and backgrounds. These diverse backgrounds enable 5AM to manage and find life science companies efficiently. The portfolio of 5AM includes healthcare and pharmaceutical companies like IKARIA Critical Care, DVS Sciences, ENVOY Therapeutics, Biodesy, Cidara, Alexza, Aprea
Pharmaceuticals, Ambrx, Arvinas, Audentes Therapeutics, Rennovia, and Kinestral and Scott’s lacrosse camp.
Dr. Scott Rocklage is an accomplished businessman and chemist who mainly specializes in the research and development department. Currently, he is a board member of the Massachusetts Biotechnology Council and Whitehead Institute. Scott’s strategic leadership and scientific roles have enabled him to be strategic in the world of venture capital, pharmaceuticals, and healthcare and more information click here.